1Gilliland DG,Tallman MS.Focus on acute leukemias.Cancer Cell,2002,1:417-420.
2Passegué E,Jamieson CH,Ailles LE,et al.Normal and leukemic hematopoiesis:are leukemias a stem cell disorder or reacquisition of stem cell characteristics? Proc Natl Acad Sci USA,2003,100 Suppl 1:11842-11849.
3Gilliland DG,Jordan CT,Felix CA.The molecular basis of leukemia.Hematology Am Soc Hematol Educ Program,2004,80-97.
4Hope KJ,Jin L,Dick JE.Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.Nat Immunol,2004,5:738-743.
5Cozzio A,Passegué E,Ayton PM,et al.Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.Genes Dev,2003,17:3029-3035.
6Krivtsov AV,Twomey D,Feng Z,et al.Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.Nature,2006,442:818-822.
7Ravandi F,Estrov Z.Eradication of leukemia stem cells as a new goal of therapy in leukemia.Clin Cancer Res,2006,12:340-344.
8Jordan CT.Unique molecular and cellular features of acute myelogenous leukemia stem cells.Leukemia,2002,16:559-562.
9Hauswirth AW,Florian S,Printz D,et al.Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.Eur J Clin Invest,2007,37:73-82.
10Hamann PR,Hinman LM,Hollander I,et al.Gemtuzumab ozogamicin,a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.Bioconjug Chem,2002,13:47-58.
